VerImmune Inc Announces Research Collaboration with Janssen to Leverage Its Unique Immuno-Oncology Therapeutic Platform | News
BALTIMORE, February 8, 2022 /PRNewswire-PRWeb/ — VerImmune Inc. (VerImmune), a biotechnology company developing a new therapeutic modality that redirects the body’s pre-existing immunity to cancer, announced that the company has entered into a research collaboration with Janssen Research & Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The deal was facilitated by Johnson & Johnson Innovation.
Verimmune is also a resident of [email protected] washington d.c.., which is part of Johnson & Johnson Innovation’s global network of life sciences incubators and plans to locate its research and development laboratories in this new state-of-the-art site located in the heart of the BioHealth Capital Region (BHCR) cluster which understand Maryland, washington d.c. and Virginia.
VerImmune’s technology platform is a new, highly configurable virus-inspired platform (ViP). Using this ViP, VerImmune has developed a novel first-in-class therapeutic approach called “anti-tumor immune redirection”. This approach uses the ViP platform (now called AIR-ViP) to redirect pre-existing natural immunity from past viral infections or childhood vaccinations to the target cancer. It is a broadly applicable treatment paradigm, based on a single therapy, that can work against multiple human cancers due to the pervasive nature of pre-existing responses to childhood vaccines and/or past infections.
“We are delighted to enter into this collaboration with Janssen and to use VerImmune’s AIR-ViP platform to advance the development of our new therapeutic modality. Our fundamental goal is to change treatment paradigms and provide patients with more innovative, yet safe and effective therapies,” said Joshua WangPh.D., Founding CEO and President of VerImmune.
Under the terms of the collaboration, VerImmune will work with Janssen immuno-oncology scientists to conduct feasibility studies to evaluate VerImmune’s proprietary Anti-Tumor Immune Redirection Virus (AIR-ViP) inspired particle technology platform.
VerImmune is a biotechnology company developing a cutting-edge cancer therapy known as anti-tumor immune redirection (AIR). This strategy uses a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or infantile immune memory to tumors. This unique mechanism of action allows us to differentiate ourselves within the competitive immuno-oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have incurable cancers due to limited options or resistance.
Joshua WangVerImmune, +1 4434498836, [email protected]